Case Report: Amyotrophic Lateral Sclerosis Treatment with Extracellular Vesicles derived from Mesenchymal Stromal Cells
Main Article Content
Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder marked by motor neuron loss, resulting in muscle weakness, respiratory failure, and death. Current treatment options offer limited survival benefit, highlighting the urgent need for novel therapeutic strategies. Extracellular vesicles (EVs), particularly those derived from human bone marrow, have shown promise in preclinical models due to their anti-inflammatory and neuroprotective properties.
We report the case of an 81-year-old male with a two-year history of ALS who received a novel investigational therapy consisting of intravenous infusions of human bone marrow-derived EVs. At baseline, the patient exhibited bulbar and respiratory involvement, as well as progressive weakness in the upper and lower extremities, and significant impairment in activities of daily living. Pulmonary function testing revealed a forced vital capacity (FVC) of 52% predicted, and the patient relied on non-invasive ventilation for up to 9 hours nightly.
The treatment was well-tolerated with no adverse events reported. Clinical monitoring showed stabilization of respiratory function, maintained ambulatory ability for short distances, and no further significant decline in bulbar or limb strength over the treatment period. Subjective improvements were noted in energy levels, mood, and overall quality of life, though these outcomes require further investigation in controlled studies.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Mehta P, Raymond J, Zhang Y, et al. Prevalence of amyotrophic lateral sclerosis in the United States, 2018. Amyotroph Lateral Scler Frontotemporal Degener. Published online August 21, 2023. https://doi:10.1080/21678421.2023.2245858
3. Raghav A, Singh M, Jeong GB, et al. Extracellular vesicles in neurodegenerative diseases: A systematic review. Front Mol Neurosci. 2022;15:1061076. Published 2022 Nov 24. https://doi:10.3389/fnmol.2022.1061076
4. Yari H, Mikhailova MV, Mardasi M, et al. Emerging role of mesenchymal stromal cells (MSCs)-derived exosomes in neurodegeneration-associated conditions: a groundbreaking cell-free approach. Stem Cell Res Ther. 2022;13(1):423. Published 2022 Aug 19. https://doi:10.1186/s13287-022-03122-5
5. Quan, J., Liu, Q., Li, P. et al. Mesenchymal stem cell exosome therapy: current research status in the treatment of neurodegenerative diseases and the possibility of reversing normal brain aging. Stem Cell Res Ther 16, 76 (2025). https://doi.org/10.1186/s13287-025-04160-5
6. van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084-2098. https://doi.org/10.1016/S0140-6736(17)31287-4
7. Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3(1):17071. https://doi.org/10.1038/nrdp.2017.71
8. Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomized controlled trial. Lancet Neurol. 2006;5(2):140–147. https://doi.org/10.1016/S1474-4422(05)70326-4
9. Chiò A, Logroscino G, Traynor BJ, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41(2):118–130. https://doi.org/10.1159/000351153
10. Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255–289. https://doi.org/10.1146/annurev-cellbio-101512-122326
11. Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2(8):569–579. https://doi.org/10.1038/nri855
12. Yáñez-Mó M, Siljander PR-M, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4(1):27066. https://doi.org/10.3402/jev.v4.27066
13. Bonafede R, Mariotti R. Exosomes and their role in amyotrophic lateral sclerosis. Neurobiol Dis. 2017;103:124–131. https://doi.org/10.1016/j.nbd.2017.04.011
14. Soria FN, Pampliega O, Bourdenx M, et al. Exosomes, an unmasked culprit in neurodegeneration? J Neurosci. 2017;37(37):9240–9247. https://doi.org/10.1523/JNEUROSCI.0741-17.2017
15. Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539(7628): 197–206. https://doi.org/10.1038/nature20413
16. Bruno S, et al. Mesenchymal stem cell-derived EVs protect against acute kidney injury. J Am Soc Nephrol. 2009;20(5):1053–1067. https://doi.org/10.1681/ASN.2008070798
17. Di Trapani M, et al. Differential and transferable modulatory effects of mesenchymal stromal cell-derived extracellular vesicles on T, B and NK cell functions. Sci Rep. 2016;6:24120. https://doi.org/10.1038/srep24120
18. Xin H, et al. MicroRNA cluster miR-17-92 enriched exosomes promote neuroplasticity and functional recovery after stroke in rats. Stroke. 2017;48(3):747–753. https://doi.org/10.1161/STROKEAHA.116.015204
19. Lee M, et al. Mesenchymal stem cell-derived small extracellular vesicles preserve hippocampal neuronal density and function in a mouse model of Alzheimer’s disease. Sci Rep. 2018;8:10713. https://doi.org/10.1038/s41598-018-29131-0
20. Bonafede R, et al. Exosome-derived microRNAs from mesenchymal stem cells: therapeutic perspectives in neurodegenerative diseases. Aging (Albany NY). 2016;8(9):2270–2291. https://doi.org/10.1083/jcb.201504057
21. Leung C, Tan SH, Barker RA. The role of extracellular vesicles in the pathophysiology of neurodegenerative diseases and their therapeutic potential. Cell Transplant. 2021;30:1–15. https://doi.org/10.1177/09636897211025262
22. Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles-based therapeutics in clinical trials – an ISEV position paper. J Extracell Vesicles. 2015;4(1):30087. https://doi.org/10.3402/jev.v4.30087
23. Feiler MS, et al. TDP-43 is intercellularly transmitted across axon terminals. J Cell Biol. 2015;211(4):897–911. https://doi.org/10.1083/jcb.201504057
24. Guo BB, et al. Therapeutic potential of human adipose-derived extracellular vesicles in amyotrophic lateral sclerosis. Front Neurosci. 2020;14:581689. https://doi.org/10.3389/fnins.2020.581689
25. Paganoni S, Macklin EA, Lee A, et al. Clinical trial outcomes and placebo effects in amyotrophic lateral sclerosis. Neurology. 2019;93(4):e358–e367. https://doi.org/10.1212/WNL.0000000000007856
26. Chio A, Hammond ER, Mora G, Bonito V, Filippini G. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009;10(5-6):310–323. https://doi.org/10.3109/17482960802566824
27. Crose, Joshua J, Arezou Crose, John T Ransom, and Amy L Lightner. 2024. “Bone Marrow Mesenchymal Stem Cell-Derived Extracellular Vesicle Infusion for Amyotrophic Lateral Sclerosis.” Neurodegenerative Disease Management 14 (3–4): 111–17. doi:10.1080/17582024.2024.2344396.